pan CEA Antibody (NCRC16): sc-53400

pan CEA Antibody (NCRC16) is a mouse monoclonal IgG1 antibody that detects carcinoembryonic antigen (CEA) in human samples through applications such as western blotting (WB) and immunoprecipitation (IP). Carcinoembryonic antigen plays a crucial role as a tumor marker, particularly in the diagnosis and monitoring of various carcinomas, making CEA (NCRC16) antibody an essential tool in clinical oncology. CEA is primarily located on the cell surface and is involved in cell adhesion processes, which are vital for maintaining tissue architecture and facilitating communication between cells. CEA presence in the serum can indicate tumor progression or recurrence, as elevated levels are often associated with malignancies. CEA is part of the CEACAM family, which exhibits structural homology to immunoglobulin variable domains, and CEA interaction with other proteins, such as integrins and growth factor receptors, underscores CEA importance in cellular signaling pathways related to cancer development and metastasis. Human CEACAM proteins are encoded by genes clustered on the long arm of chromosome 19, highlighting their evolutionary significance and potential as therapeutic targets. anti-CEA antibody (NCRC16) is therefore an invaluable resource for researchers and clinicians aiming to explore the complexities of cancer biology and improve patient outcomes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

pan CEA Antibody (NCRC16) References:

1. Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver.  |  Thomas, P., et al. 2011. Clin Exp Metastasis. 28: 923-32. PMID: 21901530
2. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.  |  Prager, GW., et al. 2014. Cancer Sci. 105: 996-1001. PMID: 24850362
3. Serum carcinoembryonic antigen (CEA) as a clinical marker in acquired idiopathic generalized anhidrosis: a close correlation between serum CEA level and disease activity.  |  Honma, M., et al. 2016. J Eur Acad Dermatol Venereol. 30: 1379-83. PMID: 26446433
4. Evaluation of carcinoembryonic antigen (CEA) density as a prognostic factor for percutaneous ablation of pulmonary colorectal metastases.  |  Huo, YR., et al. 2017. Eur Radiol. 27: 128-137. PMID: 27165139
5. HbA1c showed a positive association with carcinoembryonic antigen (CEA) level in only diabetes, not prediabetic or normal individuals.  |  Chung, S., et al. 2019. J Clin Lab Anal. 33: e22900. PMID: 31002428
6. Analytical and Clinical Evaluation of Chemiluminescent Carcinoembryonic Antigen (CEA) by HISCL-5000 Immunoanalyzer.  |  Jekarl, DW., et al. 2020. Ann Clin Lab Sci. 50: 417-422. PMID: 32581038
7. Optimal carcinoembryonic antigen (CEA) cutoff values in the diagnosis of neoplastic mucinous pancreatic cysts differ among assays.  |  Kim, D., et al. 2024. J Clin Pathol. 77: 848-852. PMID: 37940376
8. Determination of carcinoembryonic antigen (CEA) by label-free electrochemical immunosensor using functionalized boron nitride nanosheets.  |  Öndeş, B., et al. 2024. Bioelectrochemistry. 157: 108676. PMID: 38431993
9. Immunohistochemical localization of carcinoembryonic antigen (CEA), CEA-S, and nonspecific cross-reacting antigen (NCA) in carcinomas of lung.  |  Sun, NC., et al. 1983. Cancer. 52: 1632-41. PMID: 6311398
10. Carcinoembryonic antigen (CEA) assays in obstructive colorectal cancer.  |  Sugarbaker, PH. 1976. Ann Surg. 184: 752-7. PMID: 999351

The preferred CEACAM5 antibody is CEACAM5 Antibody (CI-P83-1): sc-23928.